For example, central to the efficacy of immune checkpoint blockade therapy is the requirement for cytotoxic immune cells to infiltrate tumours, whereas specifically inhibiting METTL1 exactly leads to enhanced infiltration of cytotoxic macrophages and cytotoxic T cells into tumours, indicating that METTL1 inhibitors are emerging as immune modulators of the TME and combining METTL1 inhibitors with immunotherapy may have a synergistic effect on increasing the efficacy of PCa treatment.61 Here, METTL1 is linked to neoplasm.